HC Wainwright & Co. Maintains Buy on Kymera Therapeutics, Lowers Price Target to $30
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Andrew Fein maintains a 'Buy' rating on Kymera Therapeutics (NASDAQ:KYMR), but has lowered the price target from $85 to $30.
November 03, 2023 | 12:05 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Kymera Therapeutics' price target has been lowered from $85 to $30 by HC Wainwright & Co., though the 'Buy' rating is maintained.
The lowering of the price target by HC Wainwright & Co. could potentially lead to a negative sentiment among investors, which may put downward pressure on the stock price in the short term. However, the maintained 'Buy' rating indicates that the analyst still sees potential in the company.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100